Journal
JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
Volume 173, Issue -, Pages 325-332Publisher
ELSEVIER SCIENCE SA
DOI: 10.1016/j.jphotobiol.2017.06.014
Keywords
Hypoxia; Photodynamic therapy; Riboflavin photosensitizer; Apoptosis; Light emitting diode
Categories
Ask authors/readers for more resources
Photodynamic therapy (PDT) is a safe and non-invasive treatment for cancers and microbial infections. Various photosensitizers and light sources have been developed for clinical cancer therapies. Flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD) are the cofactor of enzymes and are used as photosensitizers in this study. Targeting hypoxia and light-triggering reactive oxygen species (ROS) are experimental strategies for poisoning tumor cells in vitro. HeLa cells are committed to apoptosis when treated with FMN or FAD and exposed to visible blue light (the maximum emitted wavelength of blue light is 462 nm). Under blue light irradiation at 3.744 J/cm(2) (= 0.52 mW/cm(2) irradiated for 2 h), the minimal lethal dose is 3.125 mu M and the median lethal doses (LD50) for FMN and FAD are 6.5 mu M and 7.2 mu M, respectively. Individual exposure to visible blue light irradiation or riboflavin photosensitizers does not produce cytotoxicity and no side effects are observed in this study. The western blotting results also show that an intrinsic apoptosis pathway is activated by the ROS during photolysis of riboflavin analogues. Blue light triggers the cytotoxicity of riboflavins on HeLa cells in vitro. Based on these results, this is a feasible and efficient of PDT with an intrinsic photosensitizer for cancer research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available